Mesenchymal stem cells

On the Future Proof with Forever Labs podcast, Drs. Tad DeWald and Brett Fox talk about proactive prehab and regenerative medicine. They promote a 50/50 partnership between clinical care and personal movement to future-proof your physical health.

Mary Shaver, a 35-year-old nurse, shares her experience banking her stem cells with Forever Labs. She details why she chose to preserve her youth today to protect her health for the future.

Wyoming’s Senate File 48, the Stem Cell Freedom Act, proposes a legal framework for physicians to perform autologous stem cell therapies under IRB oversight and cGMP safety standards.

Your body's repair cells send out tiny "healing packages" that can help fix a heart after a heart attack. New medical studies show that using special patches to keep these packages in place helps the heart heal much faster.

Beast Games star and matchmaker Tessa Mac shares her powerful journey into regenerative medicine, sparked by a friend’s cancer battle and solidified by her own "aha" moment regarding biological insurance. In the inaugural episode of Future Proof with Forever Labs podcast, she shares why she decided to freeze her Mesenchymal Stem Cells (MSCs) as the ultimate "low-hanging fruit" for long-term health. From setting world records to surviving California wildfires, Tessa explains how securing her youngest, healthiest cells allows her to live a high-octane life today with zero regrets for tomorrow.

Explore Forever Labs's outlook on 2026 trends in regenerative medicine. Longevity has transitioned from biohacking to a mainstream standard of care. Discover breakthroughs in "bio-liquidity", MSC priming, and epigenetic resetting, alongside regulatory shifts in the United States empowering patients to own their biology.

A 2025 prospective observational study tested whether a single administration of **adipose-derived mesenchymal stem cells (ADSCs)** produces immediate changes in blood markers and muscle strength in people with neurodegenerative and respiratory conditions. The study measured serum cholinesterase ...

MSC-derived exosomes (tiny cell-made vesicles) can cross the blood–brain barrier and deliver regenerative signals that MSCs themselves can’t. In animal Alzheimer’s models, they boosted neurotrophic factors like BDNF and NGF (supporting neuron growth/survival), reduced pro-inflammatory molecules, and were associated with less amyloid plaque buildup and better performance on memory/cognition tasks. Early human trials are still small and preliminary, but so far look generally tolerable and show hints of reduced inflammation—meaning it’s promising, but not yet proven or ready as a standard treatment.

New findings show that certain circular RNAs can help control how your body's repair cells turn into different types of cells, which is important for healing and growth. This could lead to better treatments for conditions like osteoporosis and muscle loss. Understanding these processes may improve future healing therapies.

Loss or severe damage of the corneal epithelium (the clear, outer surface of the eye) can cause vision loss. Donor tissue for direct corneal or limbal epithelial transplantation is limited, and allogeneic grafts carry a rejection risk. Researchers are developing ways to turn a patient’s own stem cells into corneal epithelial cells for transplantation. This review summarizes what works so far with human stem cells — especially mesenchymal stem/stromal cells (MSCs) and pluripotent stem cells (ESCs

A meta-analysis of 18 clinical trials (565 patients) demonstrates that mesenchymal stem cell (MSC) therapy significantly improves pain (VAS) and knee function (IKDC, Lysholm, WOMAC) in osteoarthritis patients, with sustained efficacy up to 24 months and peak benefits at 12-24 months post-treatment. Outcomes were enhanced by arthroscopic debridement, activation agents, and lower Kellgren-Lawrence grades, but showed no dose-response to MSC numbers. MSC treatment offers promising pain relief and functional gains for knee osteoarthritis.

While mesenchymal stem cells represent an interesting cell source for regenerative medicine, several points have to be investigated to improve their use in clinical, and in particular in the elderly population. This work studied the proliferation capacity of mesenchymal stem cells isolated from human bone marrow in function of donor's age. Doubling time after in vitro culture, clonogenicity and phenotype were analyzed in 17 samples ranging from 3 to 85 years old (mean 47 ± 27). Results showed an increase in the doubling time for cell coming from old donor compared to cells coming from young ones. This was accompanied by a decrease in clonogenicity while no changes were observe in cell phenotype. In conclusion, this study showed an effect of donor's age on the proliferation capacity of mesenchymal stem cells isolated from bone marrow that was correlated to a decrease in clonogenicity. The comprehension of molecular mechanism involved in this process could help to improve the clinical application of mesenchymal stem cells.

__Increasing evidence suggests that the loss of functional stem cells may be important in the aging process.__ Our experiments were originally aimed at testing the idea that, in the specific case of age-related osteoporosis, declining function of osteogenic precursor cells might be at least partially responsible. To test this, aging female mice were transplanted with mesenchymal stem cells from aged or young male donors. We find that transplantation of young mesenchymal stem cells significantly slows the loss of bone density and, surprisingly, prolongs the life span of old mice. These observations lend further support to the idea that age-related diminution of stem cell number or function may play a critical role in age-related loss of bone density in aging animals and may be one determinant of overall longevity.